The Maudsley Staging Method: A Clinical Tool for Grading Treatment-Resistant Depression Before Escalating

The Maudsley Staging Method: A Clinical Tool for Grading Treatment-Resistant Depression Before Escalating

What It Is

The Maudsley Staging Method (MSM) is a validated clinical staging instrument for treatment-resistant depression (TRD). Developed by Fekadu and colleagues at the Maudsley Hospital (King's College London), it provides a systematic, quantified staging of TRD severity that accounts not just for number of failed treatments but for illness duration, symptom severity, and functional impairment.

The MSM produces a score from 3 to 15. Stages correspond roughly to:

• Stage 1–2 (score 3–6): Limited treatment resistance — 1 failed adequate trial
• Stage 3–4 (score 7–10): Moderate resistance — 2–3 failed trials across drug classes
• Stage 5 (score 11–15): Severe chronic TRD — multiple failed trials, prolonged episode, significant functional impairment

Why Staging Matters

The absence of a standard TRD staging system has created a persistent problem in both research and clinical practice: "treatment-resistant depression" is used to describe everything from one failed SSRI trial to 10 years of inadequate remission across all medication classes, ECT, and psychotherapy. This terminological collapse obscures dramatically different clinical realities and has led to inconsistent eligibility criteria across clinical trials, which in turn limits comparability of TRD treatment research.

In clinical practice, the absence of staging leads to premature escalation (moving to ECT after two failed trials when augmentation has not been systematically attempted), delayed escalation (continuing to adjust medications when a patient is clearly stage 5 and needs neuromodulation), and inadequate documentation of treatment history that limits specialist referrals.

The Three MSM Dimensions

Dimension 1 — Treatment failures (0–5 points): Number of adequate antidepressant trials that have not produced response, weighted by class diversity. An adequate trial = minimum effective dose × 4–6 weeks. Each failed trial from a new class adds more weight than additional trials within the same class. Maximum 5 points.

Dimension 2 — Episode duration and chronicity (0–5 points): Current episode duration from 3 months (0 points) through 1 year (2 points) to >2 years (5 points). This dimension captures the progressive neurobiological changes associated with chronic depression — including hippocampal atrophy, increased hypothalamic-pituitary-adrenal axis dysregulation, and treatment-unresponsiveness that worsens with chronicity.

Dimension 3 — Symptom severity and functional impairment (0–5 points): Combination of symptom rating (HRSD or equivalent) and functional impairment (Global Assessment of Functioning or equivalent). This prevents the staging from being based purely on treatment history, which can be measured inconsistently.

How to Use It in Practice

Step 1 — Construct a treatment history timeline: List every antidepressant and augmentation agent, dose, duration, and outcome. Use a structured form (the Massachusetts General Hospital ATHF provides a format). This step alone has clinical value — many patients cannot recall their treatment history, which creates the illusion of fewer failed trials than actually occurred.

Step 2 — Score each dimension: Apply MSM scoring criteria to the treatment history. When treatment history is incomplete, score conservatively (lower bound).

Step 3 — Determine stage: Sum to obtain total MSM score. Map to stage.

Step 4 — Use stage to guide next step:

• Stage 1–2: Systematic augmentation within current class + ensure all trials were adequate (dose + duration)
• Stage 3: Systematic class switching + consider psychotherapy specifically targeting MDD (CBASP for chronic depression)
• Stage 4: Referral to specialist TRD service; consider atypical augmentation (lithium, thyroid); raise ketamine/esketamine discussion
• Stage 5: Multidisciplinary TRD program; consider ECT; ensure inflammatory workup (CRP, thyroid, vitamin D) is complete

What the MSM Does Not Capture

The MSM predates the inflammatory subtype literature and does not incorporate biomarker information. It also predates the routine use of ketamine and does not include failed ketamine/esketamine trials in its scoring — clinicians using it in 2024-2025 should adapt the treatment history component to include neuromodulation and ketamine trials.

The MSM also does not assess treatment tolerability versus true non-response — a patient who discontinued an SSRI at week 2 due to sexual side effects is not the same as one who completed 8 weeks at therapeutic dose without response. Structured treatment history (ATHF format) captures this distinction; the MSM alone does not.

Practical resources:

• MSM scoring criteria: available in the original Fekadu et al. 2009 paper (open access)
• ATHF (Antidepressant Treatment History Form): freely available at MGH Clinical Trials Network
• Maudsley Prescribing Guidelines (annual, Wiley-Blackwell): companion reference for treatment sequencing

Tool note: The Maudsley Staging Method takes under 15 minutes to complete with a structured treatment history. For any patient presenting as TRD, completing the MSM before the consultation with a psychiatrist or specialist TRD service is one of the highest-leverage pre-referral steps a non-prescribing clinician can take — it gives the receiving clinician a structured baseline and ensures treatment escalation is documented and appropriate.

Tags: treatment-resistant-depression, staging, clinical-tool, assessment, depression, treatment-algorithm, maudsley